Docetaxel, marketed by Sanofi Aventis as Taxotere is a leading chemotherapy drug used to treat a variety of solid tumors including breast, lung and prostate.
As part of its drug delivery program for docetaxel, the company has conducted the latest study, a breast cancer xenograft in mice to evaluate the efficacy of dendrimer-docetaxel formulations in treating cancer.
The study demonstrated that dendrimer-docetaxel formulation showed a significant improvement of anticancer effect when compared to docetaxel/Taxotere alone.
Starpharma CEO Jackie Fairley said the initial results of their dendrimer-docetaxel program showed no evidence of tumors and a significant improvement in efficacy versus docetaxel in a high proportion of animals.
”These findings together with the ability of Starpharma’s dendrimers to markedly improve water solubility represent a compelling product proposition," Fairley added.